NEW YORK, November 11, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR), BioScrip, Inc. (NASDAQ: BIOS), Chemed Corporation (NYSE: CHE), Foundation Medicine, Inc. (NASDAQ: FMI), and Antares Pharma, Inc. (NASDAQ: ATRS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Avanir Pharmaceuticals, Inc. Research Report
On October 29, 2013, Avanir Pharmaceuticals, Inc. (Avanir) reported preliminary financial information for full-year FY 2013 (period ended September 30, 2013). Based on the preliminary financial information reported by the Company, total gross revenues for full-year FY 2013 are estimated to be nearly $95.9 million, while net revenues are estimated to be between $75.3 million to $76.3 million. "We are delighted with the progress of our NUEDEXTA PBA commercial business this year," said Keith Katkin, President and CEO of Avanir. "In addition, the R&D team has made great progress with our pipeline. We now have three active phase II studies of AVP-923 including MS neuropathic pain, Alzheimer's agitation, and the recently announced levodopa-induced dyskinesias in Parkinson's disease. We continue to expect top-line data from our PRIME study in MS neuropathic pain later this calendar year." The Full Research Report on Avanir Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
BioScrip, Inc. Research Report
On November 6, 2013, BioScrip, Inc. (BioScrip) reported its Q3 2013 financial results. During the quarter, the Company's revenue increased 22.6% YoY to $208.9 million. Q3 2013 net loss from continuing operations was $22.4 million, or $0.35 per diluted share, compared with a net loss of $0.6 million or $0.01 per diluted share, in Q3 2012. "Our core infusion business continued to deliver strong margins and double-digit organic revenue growth in the third quarter," said Rick Smith, President and CEO of BioScrip. "We closed the CarePoint acquisition during the quarter and our acquisitions are on track to achieve their targeted range of 12 to 14 percent long-term EBITDA margins, once fully integrated. These underlying results demonstrate our success in implementing our plan to deliver growth across a national infusion footprint." The Full Research Report on BioScrip, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Chemed Corporation Research Report
On November 6, 2013, Chemed Corporation (Chemed) announced that it will make a presentation at the 2013 Credit Suisse Healthcare Conference. The Company informed that the presentation will take place on November 12, 2013 at approximately 8:00 a.m. MT at the Phoenician Hotel in Scottsdale, AZ. The presentation will be webcast live and can be accessed through the Chemed website. The Full Research Report on Chemed Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Foundation Medicine, Inc. Research Report
On November 6, 2013, Foundation Medicine, Inc. (Foundation Medicine) reported its Q3 2013 financial results. During the quarter, the Company's revenues totaled $8.2 million, up 170.3% YoY. The Company informed that more than half of its quarterly revenues came from clinical testing. Q3 2013 net loss was $12.5 million, or $3.51 loss per basic and diluted share, compared with a net loss of $5.6 million, or $2.39 per basic and diluted share, in Q3 2012. "Results in the third quarter demonstrate the growing enthusiasm in the marketplace for our fully informative genomic profile for use across all solid tumors," said Michael Pellini, M.D., President and CEO of Foundation Medicine. "We are very encouraged by the commercial traction as the utility of FoundationOne and the information it delivers garners growing recognition among oncologists, pathologists and pharmaceutical companies. In addition, the number of scientific publications generated using our molecular information platform during the quarter continues to underscore its clinical utility and value in the care of patients with cancer." The Full Research Report on Foundation Medicine, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Antares Pharma, Inc. Research Report
On November 6, 2013, Antares Pharma, Inc. (Antares) reported its Q3 2013 financial results. The Company's revenues totaled $5.5 million, down 3.1% YoY during the quarter. Q3 2013 net loss was $0.05 per basic and diluted share, compared with a net loss of $0.03 per basic and diluted share, in Q3 2012. "Last month's approval of OTREXUP represented a strategic milestone in the transformation of Antares from a royalty based business to a specialty pharmaceutical company generating potential product revenue from proprietary in-house development programs," said Paul K. Wotton, Ph.D., President and CEO of Antares. "We believe that OTREXUP could become an important part of the treatment continuum for RA patients and look forward to launching the product early in 2014." The Full Research Report on Antares Pharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
|SOURCE Analysts' Corner|
Copyright©2012 PR Newswire.
All rights reserved